Contributions of RetinopathyRex

Contributions by RetinopathyRex, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,844 edits includes activity predating the current log.

1. 19:27, 15 Jul 2026 (diff | hist) Good manufacturing practice 5,123 ±0 add the citation for the regulatory action
2. 08:33, 30 May 2026 (diff | hist) Sharps disposal 9,432 +1,192 add the preservative point: unpreserved diluent changes the interval
3. 10:15, 2 Mar 2026 (diff | hist) Talk:SUSTAIN trial programme 400 +172 /* Retinopathy finding */ new section
4. 09:00, 2 Oct 2025 (diff | hist) AmbioPharm 1,686 +1,686 N start organisation article — registry facts and product scope only
5. 00:27, 14 Sep 2025 (diff | hist) Weight regain after discontinuation 4,670 ±0 state that no head-to-head comparison of tolerability exists for these two
6. 15:33, 20 May 2025 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,314 ±0 add the note that titration exists partly to manage these effects
7. 19:11, 30 Apr 2025 (diff | hist) Aspiration risk under anaesthesia 3,911 +31 rm the reassurance sentence; the article should report, not reassure
8. 18:22, 6 Apr 2025 (diff | hist) Hypoglycaemia 3,743 ±0 give the incidence with its denominator
9. 13:35, 11 Aug 2024 (diff | hist) List of GLP-1 receptor agonists 1,884 +268 state plainly what this list does not cover